Corcept-Lifyorli Combination Shows Responses in 59% of Ovarian Cancer Patients
Corcept said its combination with Lifyorli produced responses in 59% of patients in the phase 2 BELLA study.
Corcept said its combination with Lifyorli produced responses in 59% of patients in the phase 2 BELLA study.